Tamtam Try Tamtam free
Eli Lilly and Company logo

Eli Lilly and Company account plan

Developing medicines for needs

At a glance

Eli Lilly is an Indianapolis pharmaceutical company selling in about 90 countries, with FY2025 revenue of $65,179 million led by Mounjaro and Zepbound.

Eli Lilly and Company, founded in Indianapolis in 1876, discovers, develops, manufactures and markets human pharmaceuticals in a single reportable segment, with products sold in approximately 90 countries. Its portfolio spans cardiometabolic health (Mounjaro, Zepbound, Trulicity, Jardiance), oncology (Verzenio), immunology (Taltz) and neuroscience (Kisunla). FY2025 revenue was $65,179 million, up 45%, with net income of $20,640 million and diluted EPS of $22.95; Mounjaro and Zepbound together accounted for 56% of revenue. Lilly employed approximately 50,000 people at the end of 2025, and David Ricks is Chair, President and CEO.

Business units

Strategic priorities

Broaden impact in cardiometabolic health
Grow incretins through new indications and forms: Foundayo (oral orforglipron) launched in the U.S. for obesity in Q2 2026, retatrutide had 3 positive Phase 3 TRIUMPH trials with a U.S. submission planned for Q1 2027, and about 100 studies run across the class.
Expand into other therapeutic areas
Oncology, Immunology and Neuroscience medicines collectively grew 121% in Q2 2026; business development added vaccines, psychiatry, sleep and in vivo CAR-T programs.
Widen access to obesity medicines
The Medicare GLP-1 Bridge program gives coverage at $50 per month out of pocket from July 1, 2026 to December 31, 2027, and LillyDirect sells select medicines direct to patients.
Manufacturing capacity
A $50 billion capex agenda over five years, with new sites in North Carolina, Wisconsin, Indiana, Virginia, Texas, Alabama, Pennsylvania, Ireland, Germany and the Netherlands.
2026 financial guidance
Revenue of $85 billion to $87 billion, non-GAAP performance margin of 49% to 50.5% and non-GAAP EPS of $35.50 to $36.50.

Latest results

In Q2 2026 Lilly's revenue rose 48% to $22,974 million, on volume +60% partly offset by price -13%, and H1 2026 revenue reached $42,773 million (+51%). Q2 net income was $7,095 million (+25%) and diluted EPS $7.94, held back by $2,776 million of acquired IPR&D. Mounjaro brought $9,943 million (+91%) and Zepbound $4,928 million (+46%); outside-U.S. revenue grew 80% while prices fell 36%, mainly from Mounjaro's addition to China's National Reimbursement Drug List. Lilly raised its 2026 revenue guidance to $85 billion to $87 billion.

Investments and deals

Manufacturing build-out
Capex of $7.8 billion in 2025 (vs $5.1 billion), "meaningfully higher" ahead; the first dedicated genetic medicine plant opened in Lebanon, Indiana, and the first commercial batch was produced in Limerick, Ireland.
2026 business development
$13.3 billion paid in 2026 for Centessa, Kelonia, Orna, Ventyx and Ajax; three infectious-disease companies bought in July 2026 for up to $3.9 billion; AtaiBeckley pending at about $2.8 billion.
2025 acquisitions
Verve Therapeutics for $549 million net of cash plus a CVR, Scorpion's STX-478 and SiteOne.
AI for science
Lilly is building science foundation models on an Nvidia supercomputer and applying industrial AI to manufacturing data.

Challenges and risks

Product concentration
Mounjaro and Zepbound were 56% of 2025 revenue and 65% of H1 2026 revenue.
Pricing pressure
IRA government-set prices for Jardiance in 2026 and Trulicity and Verzenio in 2028, lower realized U.S. prices and PBM formulary moves such as CVS Caremark dropping Zepbound as preferred in July 2025.
Compounded and counterfeit incretins
Mass-compounded, counterfeit and misbranded incretins remain a stated risk.
Supply chain and manufacturing scale-up
Manufacturing scale-up, single-source materials, China-based suppliers, the BIOSECURE Act and tariffs are named risks.
Rising debt
Total debt reached $54.9 billion after a $9.0 billion bond issue in May 2026.

What leadership says

“broaden our impact on cardiometabolic health, expand our presence in other therapeutic areas, and invest to drive future growth”

David Ricks, Chair and CEO · Q2 2026 earnings call (August 5, 2026)

“While we're pleased with our progress this year so far, we're not satisfied.”

David Ricks, Chair and CEO · Q2 2026 earnings call (August 5, 2026)

“Big often creates inefficiency. So we're very focused on curbing headcount growth”

David Ricks, Chair and CEO · The Angle podcast, T. Rowe Price (November 2025)

“We expect to remain active in business development, while maintaining discipline to create value.”

Daniel Skovronsky, Chief Scientific and Product Officer · Q2 2026 earnings call (August 5, 2026)

Where a supplier can help

Manufacturing construction and equipment
The $50 billion capex agenda and new sites across the U.S. and Europe create demand for engineering, equipment, automation and validation suppliers.
Supply chain resilience
Single-source materials and China-based supplier exposure point to alternative sourcing, contract manufacturing and supply-risk tools.
Direct-to-patient and launch support
LillyDirect, the Medicare Bridge and the Foundayo launch call for pharmacy, fulfilment, patient-support and DTC marketing partners.
Integrating acquired companies
$13.3 billion of 2026 business development across CAR-T, vaccines and psychiatry needs integration, clinical operations and R&D services.
Industrial AI and data
Lilly's industrial AI on manufacturing data and science foundation models open room for data, MLOps and compute partners.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Eli Lilly and Company?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Eli Lilly and Company

What does Eli Lilly do?

Eli Lilly discovers, develops, manufactures and markets human pharmaceuticals, led by the incretins Mounjaro and Zepbound, plus oncology, immunology and neuroscience medicines.

What is Eli Lilly's revenue?

FY2025 revenue was $65,179 million, up 45%. Lilly guides to $85 billion to $87 billion of revenue for 2026.

How many employees does Eli Lilly have?

Lilly employed approximately 50,000 people at the end of 2025, approximately 27,000 of them outside the U.S.

What is Eli Lilly's strategy?

Broaden its impact on cardiometabolic health, expand into other therapeutic areas and invest in manufacturing, R&D and business development to drive future growth.

Who leads Eli Lilly?

David Ricks is Chair, President and CEO, and Lucas Montarce is CFO.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)